文献速递泌尿生殖骨肌MR

三维MR指纹成像(MRF)同时定量骨转移灶的T1和T2值:前列腺癌患者的初步验证

3D MR fingerprinting (MRF) for simultaneous T1 and T2 quantification of the bone metastasis: Initial validation in prostate cancer patients.
PubMed 文献 · Eur J Radiol · 2021-10-05

回顾性纳入30例前列腺MRI(14例前列腺癌骨转移、16例无前列腺癌对照),评估三维MRF在前列腺MRI视野内定量骨转移灶T1和T2的可行性并与ADC值比较。共83个ROI(39个骨转移、44个正常骨),转移骨ADC、非增强T2和增强T2值显著更低,非增强T1和增强T1值显著更高(P<0.001)。ADC的AUROC最低(0.685),显著低于非增强T1(1.0)、非增强T2(0.932)和增强T2(0.876)。

要点

  • 前列腺癌骨转移灶在MRF上表现为非增强和增强T1值升高、T2值降低(P<0.001)。
  • 非增强T1的AUROC为1.0,显著高于ADC的0.685(P=0.001)。
  • 非增强MRF诊断性能优于ADC,可能作为前列腺癌骨髓转移定量的替代方法。

核心结论

  • 在前列腺腺体评估期间用MRF评估骨盆骨,可为骨骼检查提供可靠的参数图;非增强MRF诊断性能高于ADC值,可能作为前列腺癌患者骨髓转移定量的替代方法。

研究设计与样本

  • 回顾性研究,纳入30例前列腺MRI:14例前列腺癌骨转移、16例无前列腺癌(对照);MRF采集两次(非增强MRF和增强MRF),生成T1和T2图;两名放射科医生独立在MRF图和ADC图上勾画ROI;采用Mann-Whitney U检验和AUROC评估两名读者T1、T2和ADC均值的组间差异。

关键影像表现/征象

  • 共83个ROI,包括39个骨转移和44个正常骨。
  • 转移骨较正常骨:两名读者平均ADC、非增强T2和增强T2值显著更低,非增强T1和增强T1值显著更高(P<0.001)。

诊断标准与关键数值

  • ADC的AUROC最低(0.685),显著低于非增强T1(1.0,P=0.001)、非增强T2(0.932,P=0.004)和增强T2(0.876,P=0.031)。

临床应用与阅片要点

  • 在前列腺MRI评估前列腺时,可同期获取骨盆MRF参数图用于骨骼评估。
  • 非增强MRF诊断性能高于ADC,可能作为前列腺癌骨髓转移定量的替代方法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate the feasibility of using 3-dimensional MRF for bone marrow evaluation in the field of view of prostate MRI for T1 and T2 quantification of prostate cancer bone metastases, as well as comparing it to the ADC value.

METHODS: In this retrospective study, 30 prostate MRIs were included: 14 cases with prostate cancer bone metastasis and 16 cases without prostate cancer (control). MRF was obtained twice before (nonenhanced [NE] MRF) and after contrast injection (contrast-enhanced [CE] MRF), and T1 and T2 maps were generated from each MRF. Two radiologists independently drew regions of interest (ROIs) on the MRF maps and the ADC maps. Mann-Whitney U tests and the area under the receiver operating characteristic curve (AUROC) evaluated the two-reader means of T1, T2 and ADC values between bone metastasis and normal bone.

RESULTS: There were 83 ROIs, including 39 bone metastases and 44 normal bone. The two-reader average ADC, NE T2 and CE T2 values were significantly lower and NE T1 and CE T1 values were significantly higher in metastatic bone compared with normal bone (P < 0.001). The AUROC of the ADC was lowest (0.685), which was significantly lower than those of NE T1 (1.0, P = 0.001), NE T2 (0.932, P = 0.004), and CE T2 (0.876, P = 0.031).

CONCLUSION: MRF to assess the pelvic bone during a prostate gland evaluation provides a reliable parametric map for skeletal work-up. With higher diagnostic performance than the ADC value, NE MRF is a potential alternative for quantifying bone marrow metastases in prostate cancer patients.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Choi MH, Lee SW, Kim HG, et al. 3D MR fingerprinting (MRF) for simultaneous T1 and T2 quantification of the bone metastasis: Initial validation in prostate cancer patients. Eur J Radiol. 2021. PMID: 34638082. doi:10.1016/j.ejrad.2021.109990

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。